NCT05063916 2026-02-27
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
25 trialsNCT06317311 2025-07-25
RUBY-J
GlaxoSmithKline
Phase 2 Active not recruiting
NCT04807166 2024-07-03
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Active not recruiting
NCT05910177 2024-03-06
Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin
Fujian Cancer Hospital
Phase 2 Recruiting
NCT03549273 2024-02-07
Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions
Catalysis SL
Phase 2 Unknown
NCT05541146 2023-03-23
Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis
Instituto do Cancer do Estado de São Paulo
Phase 2 Unknown
NCT02440425 2022-10-07
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03562897 2022-07-06
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
Catalysis SL
Phase 2 Completed
NCT00420381 2020-12-19
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01519869 2020-12-14
Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
University of Kentucky
Phase 2 Completed
NCT04556071 2020-11-10
AVANIRA3
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT04566952 2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2 Unknown
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT01610869 2019-05-29
METRO-BIBF
University College, London
Phase 2 Completed
NCT00326885 2018-10-17
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Neovii Biotech
Phase 2 Completed
NCT00408603 2017-07-27
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
Sunesis Pharmaceuticals
Phase 2 Completed
NCT01184053 2017-06-14
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT01342653 2016-11-21
HIPEC
Hospital General Universitario Gregorio Marañon
Phase 2 Suspended
NCT01175772 2015-06-23
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
HaEmek Medical Center, Israel
Phase 2 Terminated
NCT01379534 2015-05-20
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Novartis
Phase 2 Completed
NCT02017678 2014-09-17
Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin
Mount Sinai Hospital, Canada
Phase 2 Withdrawn
NCT00050440 2013-01-08
Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00377429 2012-07-19
Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy
Neovii Biotech
Phase 2 Completed
NCT00035100 2012-04-16
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
Novartis
Phase 2 Completed
NCT00332696 2011-09-23
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Novartis
Phase 2 Completed